NCT07435337 Effect of Nalbuphine Versus Fentanyl on Hemdoynamic Effects of Laryngoscopy
| NCT ID | NCT07435337 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Rawalpindi Institute of Cardiology |
| Condition | Laryngoscopy |
| Study Type | INTERVENTIONAL |
| Enrollment | 98 participants |
| Start Date | 2026-02-21 |
| Primary Completion | 2026-05-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 98 participants in total. It began in 2026-02-21 with a primary completion date of 2026-05-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Participants will undergo routine pre-operative evaluation. An intravenous line will be placed in the recovery area. On arrival in the operating room, standard monitoring (blood pressure, heart rate, oxygen saturation, ECG, breathing monitor, and temperature) will be applied. A central venous catheter and an arterial line will be inserted under local anesthesia using sterile technique. Before anesthesia induction, patients will receive premedication including midazolam and an opioid pain-relief injection given slowly through the vein. General anesthesia will then be induced with etomidate. After adequate sedation, a muscle relaxant (atracurium) will be administered, and the patient will be ventilated with 100% oxygen using a face mask. The breathing tube will then be inserted and correct placement confirmed. During surgery, anesthesia will be maintained with oxygen, sevoflurane gas, and a continuous atracurium infusion. Hemodynamic parameters such as heart rate and blood pressure will be monitored throughout the peri-intubation and intraoperative period.
Eligibility Criteria
Inclusion Criteria: * Weighing 40-70kg * ASA III of either sex * Undergoing cardiac surgery with CPB Exclusion Criteria: • History of Drug Allergy • Pre-existing Asthma • Renal or Hepatic dysfunction • Extreme obesity • Pregnant / lactating patients • Difficult intubation/prolonged intubation
Contact & Investigator
Qudsia Qureshi, MBBS
STUDY CHAIR
Head of Department of Anesthesia
Frequently Asked Questions
Who can join the NCT07435337 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 60 Years, studying Laryngoscopy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07435337 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07435337 currently recruiting?
Yes, NCT07435337 is actively recruiting participants. Contact the research team at ayemonfatima@gmail.com for enrollment information.
Where is the NCT07435337 trial being conducted?
This trial is being conducted at Rawalpindi, Pakistan.
Who is sponsoring the NCT07435337 clinical trial?
NCT07435337 is sponsored by Rawalpindi Institute of Cardiology. The principal investigator is Qudsia Qureshi, MBBS at Head of Department of Anesthesia. The trial plans to enroll 98 participants.